Insights
Short pieces on how health-system pharmacy actually makes decisions about access, evidence, and cost. Written for pharmacy leaders, cancer center teams, and the industry folks who work with them. All of it non-promotional and product-neutral.
Written from the operator's seat, not the vendor's.
Formulary ·
The P&T packet is only part of it. Here is the sequence a new oncology agent moves through inside a health system, and the questions that decide whether it gets on formulary.
ReadAccess ·
Most delay is not payer review time. It sits in benefits investigation, incomplete referrals, and the handoffs between clinic, pharmacy, and hub. Where the days really go.
Read340B ·
340B savings are an institutional resource, not an automatic patient discount. How covered entities connect program savings to what a patient pays at the counter.
ReadManufacturers ·
Manufacturers plan payer access early. Provider-side design, like distribution and hub structure, gets less of that same attention. A limited-distribution example, and where AI is starting to change prior authorization.
ReadManufacturers ·
Site-of-care shifts, contract pharmacy disputes, and duplicate-discount scrutiny are pulling 340B into conversations field teams used to be able to ignore. What that means in practice.
ReadManufacturers ·
A newly launched drug has no ASP data yet, so it gets paid differently than it will a year later. Why that structural gap shapes early adoption decisions.
ReadBring it to a 30-minute call. If it is a short answer, you will get it on the call.